The Gleevec (imatinib) Trial - Cancer Science

Relevant Publications

Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.

Issue Release: 2023

Advances in kinase targeting: current clinical use and clinical trials.

Issue Release: 2014

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.

Issue Release: 2014

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.

Issue Release: 2014

Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.

Issue Release: 2012

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Issue Release: 2011

Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report.

Issue Release: 2010

Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.

Issue Release: 2010

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.

Issue Release: 2010

Merkel cell carcinoma: lack of KIT positivity and implications for the use of imatinib mesylate.

Issue Release: 2009

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.

Issue Release: 2009

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Issue Release: 2008

Phase II open label trial of imatinib in polycythemia rubra vera.

Issue Release: 2008

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

Issue Release: 2007

A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.

Issue Release: 2006

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Issue Release: 2006

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

Issue Release: 2005

Molecularly targeted therapy for gastrointestinal cancer.

Issue Release: 2005

[Diagnosis and treatment of chronic myelogenous leukemia].

Issue Release: 2005

Recent progress in management of advanced prostate cancer.

Issue Release: 2005

What Are the Treatment Options for Herpesvirus-Related Cancers?

Why Do Responses to Cancer Treatments Vary?

Can Premiums be Reduced?

Are There Tools to Help Manage Information?

How Does fMRI Work in Cancer Detection?

Are There Any Other Health Benefits of Hands-Free Devices?

What impact do volunteers have on cancer patients and the community?

What Role Does Nutritional Counseling Play?

What are the Advantages of the Log Rank Test?

What Are Direct KRAS Inhibitors?

The Gleevec (imatinib) Trial - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics